Lucy Ibrahim, MD
Addiction Medicine · Romeoville, ILNPI 1184610107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 26.6% of the total. Reporting peaked in 2019 at $255 and has fallen 91.2% since, to $22 in 2022.
Across 19 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$96
- AbbVie$87
- Otsuka America Pharmaceutical, Inc.$48
- Takeda Pharmaceuticals U.S.A., Inc.$37
- Sunovion Pharmaceuticals Inc.$36
- Shire North American Group Inc$22
- plus $36 from 2 others
Across 6 payments — averaging $499,037 each. An ownership or investment interest held by the physician or an immediate family member.
- Spinecraft, LLC$3M
What the payments were for
- Food & beverage$33191%
- Education$329%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $96 |
| AbbVie(2 entities) | 4 | $87 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Shire North American Group Inc | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $14 |
How this compares
$363 in reported general payments places this provider in the 60th percentile of 47 addiction medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $128,270 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,134 |
| Lurasidone Hcl | 31 | $7,234 |
| Paliperidone ErPaliperidone | 34 | $5,218 |
| Methylphenidate Er (La)Methylphenidate Hcl | 21 | $2,568 |
| Divalproex Sodium | 67 | $2,217 |
| Quetiapine Fumarate | 95 | $1,333 |
| Aripiprazole | 28 | $1,146 |
| Bupropion XlBupropion Hcl | 37 | $939 |
| Hydroxyzine Hcl | 35 | $898 |
| Sertraline Hcl | 73 | $656 |
| Bupropion Hcl SrBupropion Hcl | 22 | $561 |
| Alprazolam | 51 | $500 |
| Fluoxetine Hcl | 42 | $443 |
| Risperidone | 54 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $11,13423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 47 addiction medicine providers in Illinois.
Other addiction medicine in Romeoville
- Leonard SpishakoffRomeoville$11K
- Roueen RafeyanChicago$2.4M
- Abhinav SinglaJoliet$115K
- Phillip HeldingHinsdale$8K
- Adeyemi FatokiOttawa$8K
- Michael BlainEldorado$6K
- Albert TanlimWatseka$5K
- Francesco TaniChicago$4K
- Neha DattaOrland Park$4K
- Paul BonucciPrinceton$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.